FLT3-ITD levels before and after induction. Banked genomic DNA samples from the patients listed in Table 1 were analyzed by MRD assay. (A) One-way analysis of the difference in FLT3-ITD levels at remission, comparing patients treated with chemotherapy only with patients treated with chemotherapy plus an FLT3 inhibitor. (B) Graphic comparison of an FLT3-ITD level decrease from diagnosis to remission. Although the difference in %ITD levels between induction and postinduction is statistically significant in both groups (P value 6.315e-06 for −FLT3, and P value 7.78e-05 for patients with chemotherapy plus FLT3 inhibitor using Wilcoxon rank sum test), the %ITD levels in patients with chemotherapy only are much higher than in the former group, and the difference between such groups at the postinduction level is significant (P value .04563 on a Wilcoxon rank sum test).